Neuroendocrine, immune, and local responses related to temporomandibular disorders.
Orofacial pain frequently originates from pathologic conditions in the masticatory muscles or temporomandibular joints (TMJs). The mediators and mechanisms that monitor pain and inflammation, centrally or peripherally, are of great interest in the search for new treatment modalities. The neuropeptides substance P (SP), calcitonin gene-related peptide (CGRP), and neuropeptide Y (NPY) have all been found at high levels in the synovial fluid of arthritic TMJs in association with spontaneous pain, while serotonin (5-HT) has been found in association with hyperalgesia/allodynia of the TMJ. Interleukin-1 beta (IL-1 beta) and tumor necrosis factor alpha (TNF alpha) have been found in arthritic TMJs, but not in healthy TMJs, in association with hyperalgesia/allodynia of the TMJ as well as spontaneous pain. Anterior open bite, which may be a clinical sign of TMJ destruction, has been found in association with high levels of CGRP, NPY, and IL-1 beta in the synovial fluid of the TMJ. Interleukin-1 beta has also been related to radiographic signs of joint destruction. Prostaglandin E2 (PGE2) and leukotriene B4 (LTB4) are both present in the arthritic TMJ, and PGE2 has been shown to be associated with hyperalgesia/allodynia of the TMJ. Very little is known about pain and inflammatory mediators in muscles. However, we know that 5-HT and PGE2 are involved in the development of pain and hyperalgesia/allodynia of the masseter muscle in patients with fibromyalgia, whereas local myalgia (myofascial pain) seems to be modulated by other, as yet unknown mediators. Interaction between the peripheral nervous system (sensory and sympathetic nerves), the immune system, and local cells is probably of great importance for the modulation of pain and inflammation in the TMJ and orofacial musculature.
Kopp
S
S
Departments of Clinical Oral Physiology and Clinical Research, Institute of Odontology, Karolinska Institutet, Box 4064, S-141 04 Huddinge, Sweden. sigvard.kopp@ofa.ki.se
D001168:Arthritis / Q000276:immunology / Q000503:physiopathology; D015740:Calcitonin Gene-Related Peptide / Q000502:physiology; D015232:Dinoprostone / Q000502:physiology; D005157:Facial Pain / Q000276:immunology / Q000503:physiopathology*; D005356:Fibromyalgia / Q000503:physiopathology; D006801:Humans; D006930:Hyperalgesia / Q000503:physiopathology; D018836:Inflammation Mediators / Q000502:physiology; D007375:Interleukin-1 / Q000502:physiology; D007975:Leukotriene B4 / Q000502:physiology; D008406:Masseter Muscle / Q000503:physiopathology; D015213:Neuroimmunomodulation / Q000502:physiology; D009478:Neuropeptide Y / Q000502:physiology; D009479:Neuropeptides / Q000502:physiology*; D009490:Neurosecretory Systems / Q000503:physiopathology*; D024343:Open Bite / Q000503:physiopathology; D012701:Serotonin / Q000502:physiology; D013373:Substance P / Q000502:physiology; D013582:Synovial Fluid / Q000737:chemistry; D013705:Temporomandibular Joint Disorders / Q000276:immunology / Q000503:physiopathology*; D014409:Tumor Necrosis Factor-alpha / Q000502:physiology
D018836:Inflammation Mediators; D007375:Interleukin-1; D009478:Neuropeptide Y; D009479:Neuropeptides; D014409:Tumor Necrosis Factor-alpha; D007975:Leukotriene B4; D012701:Serotonin; D013373:Substance P; D015740:Calcitonin Gene-Related Peptide; D015232:Dinoprostone